| Document and Entity Information | Jul. 16, 2024 |
| Cover [Abstract] | |
| Amendment Flag | true |
| Amendment Description | As previously reported on July 16, 2024, on June 26, 2024, the Board of Directors of Alaunos Therapeutics, Inc. (the “Company”) approved the filing with the Secretary of State of the State of Delaware, to occur on July 16, 2024, of a Third Amended and Restated Certificate of Incorporation (the “Charter Amendment”) in order to effect a reverse stock split of the Company’s common stock at a ratio of 1-for-10 (the “Reverse Split”) (the "Initial 8-K"). The information set forth in the Initial 8-K is incorporated herein by reference. |
| Entity Central Index Key | 0001107421 |
| Document Type | 8-K/A |
| Document Period End Date | Jul. 16, 2024 |
| Current Fiscal Year End Date | --12-31 |
| Entity Registrant Name | ALAUNOS THERAPEUTICS, INC. |
| Entity Incorporation State Country Code | DE |
| Entity File Number | 001-33038 |
| Entity Tax Identification Number | 84-1475642 |
| Entity Address, Address Line One | 2617 Bissonnet St |
| Entity Address, Address Line Two | Suite 225 |
| Entity Address, City or Town | Houston |
| Entity Address, State or Province | TX |
| Entity Address, Postal Zip Code | 77005 |
| City Area Code | (346) |
| Local Phone Number | 355-4099 |
| Written Communications | false |
| Soliciting Material | false |
| Pre Commencement Tender Offer | false |
| Pre Commencement Issuer Tender Offer | false |
| Security 12b Title | Common Stock, par value $0.001 per share |
| Trading Symbol | TCRT |
| Security Exchange Name | NASDAQ |
| Entity Emerging Growth Company | false |
